Much of Bayer AG's third quarter earnings call fixated on the group's recent reorganization to be a "life science only" company and the competitive benefits of this decision.
Under this reorganization Bayer has spun-out its material science business – which in the third quarter floated on the Frankfurt...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)


